An anti-cancer drug, pazopanib, which is marketed as Votrient™ in the U.S. and Europe by its developer, GlaxoSmithKline, was developed in part by research at the U.S. Department of Energy’s Advanced Photon Source (APS) at Argonne National Laboratory.